Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013

  title={Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013},
  author={Aparna Schweitzer and Johannes Horn and Rafael T. Mikolajczyk and G{\'e}rard Krause and J{\"o}rdis J Ott},
  journal={The Lancet},

Figures and Tables from this paper

Prevalence of chronic hepatitis B virus infection in Thailand: a systematic review and meta-analysis.
  • Charline Leroi, Pierrick Adam, G. Jourdain
  • Medicine
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • 2016
The prevalence of hepatitis B virus infection in Bangladesh: a systematic review and meta-analysis
A low intermediate prevalence ofHBV infection in Bangladesh is reported, which is currently higher than the global prevalence of HBV infection (3.5%) and the Egger's test statistics, Begg and Mazumdar's rank correlation test, and the absence of publication bias are indicated.
Hepatitis B virus infection in Nigeria: a systematic review and meta-analysis of data published between 2010 and 2019
An up-to-date review on the prevalence of HBV in Nigeria is presented, which will provide critical data to optimise and assess the impact of current prevention and control strategies, including disease surveillance and diagnoses, vaccination policies and management for those infected.
Surveillance-Based Estimate of the Prevalence of Chronic Hepatitis B Virus Infection, New York City, 2016
The current burden of chronic HBV infection in New York City, especially for non–US-born residents, is substantial and a renewed focus and dedication of resources is required to increase the number of new diagnoses and improve provider capacity to care.
Prevalence and predictors of hepatitis B virus (HBV) infection in east Africa: evidence from a systematic review and meta-analysis of epidemiological studies published from 2005 to 2020
The burden of HBV is still high, with the male sex, blood transfusion, body scarification, and HIV seropositivity being potential predictors of infection, and it is important to scale up control and prevention measures targeting persons at high risk.
Hepatitis B Virus Infection in the General Population of Iran: An Updated Systematic Review and Meta-Analysis
In total, Iran was classified within the low–intermediate HBV prevalence areas (2% - 4%), while according to recent data (after 2010), Iran was classification within the high-risk prevalence areas (< 2%), indicating that preventive measures conducted in Iran have been effective.
Hepatitis B infection in the general population of China: a systematic review and meta-analysis
The prevalence ofHBV infection in the general population of China was classified as higher intermediate prevalence (5–7.99%), of which more than 90% of the HBV infection population included adults older than 20 years, which was higher than that in children.
Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review
Wide variation in HCV and HBV prevalence across EU/EEA countries for which estimates were available is found, as well as variability between groups often considered a proxy for the general population.
Chronic hepatitis B and C infections in the Netherlands: estimated prevalence in risk groups and the general population
The total number of ever chronically infected individuals in the Netherlands in 2016 was determined using a modified workbook method using population size and prevalence estimates from studies in the general and high-risk population to help the design and evaluation of prevention and control policies.


Epidemiology of hepatitis B in Canada.
  • J. Zhang, S. Zou, A. Giulivi
  • Medicine, Biology
    The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses
  • 2001
Ongoing surveillance and research are required to assess risk factors for HBV transmission, evaluate the effectiveness of immunization programs and monitor the impact of HBsAg escape mutants.
Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening
There is evidence that HCV screening of PWID and HBsAg screening of pregnant women and migrants is cost-effective and cost-effectiveness analyses may need to take effect of antiviral treatment on preventing HBV and HCV transmission into account.
Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areasr
Results of a simple compartmental model suggest that similar rates of horizontal transmission are sufficient to generate the similar patterns between A50 and the prevalences of carriers, and interrupting horizontal transmission by mass immunization is expected to have a significant, nonlinear impact on the rate of acquisition of new carriers.
Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review
There are large age-group and regional differences in CHB prevalence in Turkey, where CHB remains a serious health problem.
Hepatitis B virus in Pakistan: A systematic review of prevalence, risk factors, awareness status and genotypes
Mass vaccination and awareness programs should be initiated on urgent basis especially in populations with HBV infection rates of more than 5%.
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
  • D. Lavanchy
  • Medicine, Biology
    Journal of viral hepatitis
  • 2004
More efficacious treatments, mass immunization programs, and safe injection techniques are essential for eliminating HBV infection and reducing global HBV‐related morbidity and mortality.
The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions
Age- and region-specific HBeAg prevalence estimates are crucial for understanding the epidemiology of HBV and for prioritizing implementation of WHO`s prevention recommendations for all infants to receive the first dose of hepatitis B vaccine within 24 hours of birth.